点击蓝字 关注我们
晚期非小细胞肺癌（NSCLC）的治疗策略包括铂类双药化疗、免疫疗法和靶向疗法，具体治疗手段取决于分子生物标志物的检测情况。晚期NSCLC患者目前尚未满足的医疗需求包括：接受免疫联合治疗失败后缺乏新的治疗选择，对靶向治疗产生耐药以及缺少改善疗效的策略[1-3]。
本文作者：
Dr. Augusto Valdivia
西班牙巴塞罗那Vall d’Hebron大学医院
Vall d’Hebron肿瘤研究所
Dr. Patricia Iranzo
西班牙巴塞罗那Vall d’Hebron大学医院
Vall d’Hebron肿瘤研究所
Dr. Nuria Pardo
西班牙巴塞罗那Vall d’Hebron大学医院
Vall d’Hebron肿瘤研究所
Dr. Enriqueta Felip
西班牙巴塞罗那Vall d’Hebron大学医院
Vall d’Hebron肿瘤研究所
表1. NSCLC ADC试验中报告的最常见的任何级别AE和≥3级AE
限制用药周期数
ADC联合免疫/靶向疗法
参考文献
1.Hendriks LE, Kerr KM, Menis J, et al; ESMO Guidelines Committee. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.Ann Oncol. 2023;34(4):358-376.
2.Hendriks LE, Kerr KM, Menis J, et al; ESMO Guidelines Committee. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.Ann Oncol. 2023;34(4):339-357.
3.Meyer M, Fitzgerald B, Paz-Ares L, et al. New promises and challenges in the treatment of advanced non-small-cell lung cancer.Lancet. 2024;404(10454):803-822.
4.Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy.Signal Transduct Target Ther. 2022;7(1):93.
5.Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy.Nat Rev Clin Oncol. 2021;18(6):327-344.
6.Goto K, Goto Y, Kubo T, et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial.J Clin Oncol. 2023;41(31):4852-4863.
7.Paz-Ares LG, Juan-Vidal O, Mountzios GS, et al. Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small-cell lung cancer: the randomized, open-label phase III EVOKE-01 study.J Clin Oncol. 2024;42(24):2860-2872.
8.Ahn M, Lisberg A, Paz-Ares L, et al. LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small-cell lung cancer (NSCLC): results of the randomized phase III study TROPION-Lung01.Ann Oncol. 2023;34:S1305-S1306.
9.Yu HA, Goto Y, Hayashi H, et al. HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor and platinum-based chemotherapy.J Clin Oncol. 2023;41(35):5363-5375.
10.Camidge DR, Bar J, Horinouchi H, et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial.J Clin Oncol. 2024;42(25):3000-3011.
11.Tarantino P, Ricciuti B, Pradhan SM, Tolaney SM. Optimizing the safety of antibody-drug conjugates for patients with solid tumours.Nat Rev Clin Oncol. 2023;20(8):558-576.
12.Socinski MA, Morris DE, Masters GA, Lilenbaum R; American College of Chest Physicians. Chemotherapeutic management of stage IV non-small cell lung cancer.Chest. 2003;123(suppl 1 ):226S-243S.
13.Smith IE, O’Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin.J Clin Oncol. 2001;19(5):1336-1343.
14.Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.J Clin Oncol. 2002;20(5):1335-1343.
15.Park JO, Kim SW, Ahn JS, et al. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer.J Clin Oncol. 2007;25(33):5233-5239.
16.Rossi A, Chiodini P, Sun JM, et al. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.Lancet Oncol. 2014;15(11):1254-1262.
17.Lu D, Gillespie WR, Girish S, et al. Time-to-event analysis of polatuzumab vedotin-induced peripheral neuropathy to assist in the comparison of clinical dosing regimens.CPT Pharmacometrics Syst Pharmacol. 2017;6(6):401-408.
18.Iwata TN, Ishii C, Ishida S, Ogitani Y, Wada T, Agatsuma T. A HER2-targeting antibody–drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model.Mol Cancer Ther. 2018;17(7):1494-1503.
19.Haratani K, Yonesaka K, Takamura S, et al. U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation.J Clin Invest. 2020;130(1):374-388.
20.Goto Y, Su W, Levy B, et al. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).J Clin Oncol. 2023;41:16s (suppl; abstr 9004).
21.<jrn>Comer F, Mazor Y, Hurt E, et al. AZD9592: an EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond.Cancer Res. 2023;83:7s (suppl; abstr 5736).
声 明
凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。
